Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Janux Therapeutics, Inc.

Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations. Janux is developing a broad pipeline with lead programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2), with all of its programs currently in the IND-enabling or discovery stage.

EcoR1 Capital

Surveyor Capital

Avalon Ventures

Hartford HealthCare Endowment

Samsara BioCapital

Biotechnology Value Fund

Bregua Corporation

BVF Partners

OrbiMed

Logos Capital

RA Capital Management

Janux Therapeutics

Today we honor Dr. Martin Luther King Jr. by taking the day to volunteer and celebrate the civil rights leader’s life and legacy. #MLKDay is the only federal holiday designated as a National Day of Service. By volunteering to improve our communities and valuing and respecting all, we honor Dr. King and work together to create a more just and equitable society. 

Visit @AmeriCorps, to find out more about #MLKDayOfService: https://lnkd.in/gX9pXAph

Congrats to Co-Founder Thomas DiRaimondo, Ph.D., on his promotion to Chief Scientific Officer!  

“Tommy was essential in our initial efforts to discover and engineer a tumor-activated technology for solid tumors and has since played a critical role in optimizing the applications for our #TRACTr and #TRACIr platforms while supporting our clinical programs.”

We look forward to his further transformative contributions as we continue to advance our platforms and preclinical pipeline.

Read the release here: https://lnkd.in/dwGhatDa

We are grateful to our team for a great year! Janux will be closed for the holiday so we can spend time with our family and friends. We will return refreshed and ready in the New Year to continue our mission of developing meaningful new immunotherapies to improve outcomes for those fighting cancer.

#LifeatJanux #HappyHolidays

As #Movember2023 comes to a close, we want to thank everyone who joined and supported us in raising awareness for #prostatecancer and #menshealth. For Janux, #Movember helps fuel our inspiration and mission to develop meaningful new immunotherapies to improve outcomes in #mCRPC. 
 
#ProstateCancerAwareness

For International #PrideInSTEM Day, we share our support for #EqualityInSTEM and the LGBTQIA+ community 🏳️🌈. Embracing diversity, in all its forms, is vital for the future of scientific innovation.

Learn more about Pride in STEM - https://prideinstem.org/

Janux is participating in #Movember2023 to raise awareness for #prostatecancer. Here’s photos from our team members that are growing mustaches – some from Day 0 and 15! 

Early detection is key. Understand your risk and when to take action: https://lnkd.in/gPykynKt 

#prostatecancerawareness #GoJanux #Movember

Today we announced our Q3 2023 financial results and business highlights. Enrollment is ongoing for our PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008) #clinicaltrials. With a strong financial foundation, we're well-positioned to advance our innovative cancer #immunotherapies.
 
Read the full press release for more details: https://lnkd.in/gmvkquyf
 
$JANX #Q3Earnings #ProstateCancer #TRACTr #TRACIr #TCellEngagers

#Movember2023 has arrived, and Janux is proud to participate in raising awareness for #menshealth and #prostatecancer. Learn more about #Movember and prostate cancer here: https://lnkd.in/gPykynKt  

We will share more progress on our mustaches 👨🦰 later in the month!  

#MensHealthAwareness #ProstateCancerAwareness #GoJanux

At Janux, we believe that each member of the team contributes to our overall mission. We succeed as a team, and we grow as a team. Come join us!

#SucceedAtJanux #GrowAtJanux

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	267K -	428K 60.30%	2.46M 474.30%	2.16M 12.16%	2.42M 12.27%
accumulated other comprehensive income loss			-270K -	-1.53M 468.52%	665K 143.32%
cash and cash equivalents	658K -	7.81M 1,087.39%	35.58M 355.42%	51.43M 44.53%	19.20M 62.66%
cash and short term investments	658K -	7.81M 1,087.39%	374.96M 4,699.24%	327.02M 12.79%	344.03M 5.20%
common stock	1K -	1K 0%	41K 4,000%	42K 2.44%	46K 9.52%
deferred revenue		1.95M -	5.16M 164.77%	5.41M 4.71%	1.71M 68.46%
deferred revenue non current		6.05M -	700K 88.43%	2.22M 217.29%
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory					-2.20M -
long term debt				24.54M -	23.02M 6.18%
long term investments					816K -
net debt	3.34M -	-7.81M 333.78%	-35.39M 352.94%	-26.12M 26.19%	5.34M 120.43%
net receivables		8M -			2.20M -
other assets
other current assets		249K -	2.05M 724.90%	5.42M 164.02%	5.21M 3.87%
other current liabilities	360K -	52K 85.56%	4.98M 9,480.77%	8.18M 64.17%	7.39M 9.68%
other liabilities
other non current assets			1.21M -	2.21M 82.62%	2.51M 13.74%
other non current liabilities		21.62M -
othertotal stockholders equity	10K -	100K 900%	34.14M 34,043%	432.70M 1,167.33%	512.40M 18.42%
preferred stock			379.82M -
property plant equipment net	21K -	155K 638.10%	1.60M 930.32%	29.36M 1,738.76%	27.84M 5.19%
retained earnings	-7.96M -	-14.74M 85.28%	-47.41M 221.67%	-110.47M 133.00%	-168.76M 52.77%
short term debt	4M -	751K 81.23%	194K 74.17%	763K 293.30%	1.52M 98.82%
short term investments			339.38M -	275.59M 18.80%	324.82M 17.86%
tax assets
tax payables
total assets	679K -	16.22M 2,288.37%	379.82M 2,242.13%	364.01M 4.16%	380.41M 4.50%
total current assets	658K -	16.06M 2,341.03%	377.02M 2,247.27%	332.44M 11.82%	349.24M 5.05%
total current liabilities	4.63M -	3.18M 31.25%	12.80M 302.29%	16.51M 28.99%	13.03M 21.05%
total debt	4M -		194K -	25.30M 12,943.81%	24.54M 3.02%
total investments			339.38M -	275.59M 18.80%	324.82M 17.86%
total liabilities	8.62M -	30.86M 257.82%	13.50M 56.26%	43.27M 220.59%	36.06M 16.67%
total liabilities and stockholders equity	679K -	16.22M 2,288.37%	379.82M 2,242.13%	364.01M 4.16%	380.41M 4.50%
total non current assets	21K -	155K 638.10%	2.81M 1,709.68%	31.57M 1,025.53%	31.17M 1.28%
total non current liabilities	4.00M -	27.67M 592.54%	700K 97.47%	26.76M 3,723.29%	23.02M 13.97%
total stockholders equity	-7.94M -	-14.64M 84.26%	366.33M 2,602.58%	320.74M 12.44%	344.35M 7.36%

COM:JANUXRX

Janux Therapeutics

Last Close

46.50

22/11 21:00

Market Cap

2.15B

Beta: -

Volume Today

797.30K

Avg: -

Preview